Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Choi, Jin Ok ^a   Lee, Mi Hee ^a   Park, Hae Young ^a   Jung, Sung Chul ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; CERAMIDE TRIHEXOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME REPLACEMENT; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FABRY DISEASE; GENE THERAPY; GENE TRANSFER; GLOMERULUS; HEART; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY PROXIMAL TUBULE; LIVER; LIVER FUNCTION TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOTYPING; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; TAIL; TREATMENT DURATION; VIRUS RECOMBINATION; WESTERN BLOTTING; ADENO ASSOCIATED VIRUS; ANIMAL; GENE VECTOR; GENETICS; HUMAN; METABOLISM; TRANSGENIC MOUSE;

ADENO-ASSOCIATED VIRUS; MUS;

ALPHA-GALACTOSIDASE; ANIMALS; DEPENDOVIRUS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; MICE, TRANSGENIC; TRIHEXOSYLCERAMIDES;

EID: 77950807425     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-26     Document Type: Article

References (36)

1. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. RO Brady AE Gal RM Bradley E Martensson AL Warshaw L Laster, N Engl J Med 1967 276 1163 1167 6023233
2. Enzyme replacement for lysosomal diseases. RO Brady, Annu Rev Med 2006 57 283 296 10.1146/annurev.med.57.110104.115650 16409150
3. Fabry disease in childhood. RJ Desnick RO Brady, J Pediatr 2004 144 20 26 10.1016/j.jpeds.2004.01.051 15126980
4. Fabry disease: immune-cytochemical characterization of neuronal involvement. GA DeVeber GA Schwarting EH Kolodny NW Kowall, Ann Neurol 1992 31 409 415 10.1002/ana.410310410 1375013
5. Infusion of -galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. R Schiffmann GJ Murray D Treco P Daniel M Sellos-Moura M Myers JM Quirk GC Zirzow M Borowski K Loveday, Proc Natl Acad Sci USA 2000 97 365 370 10.1073/pnas.97.1.365 10618424
6. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. CM Eng N Guffon WR Wilcox DP Germain P Lee S Waldek L Caplan GE Linthorst RJ Desnick, N Engl J Med 2001 345 9 16 10.1056/NEJM200107053450102 11439963
7. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. K Lee X Jin K Zhang L Copertino L Andrews J Baker-Malcolm L Geagan H Qiu K Seiger D Barngrover JM McPherson, Glycobiology 2003 13 305 313 10.1093/glycob/cwg034 12626384
8. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. R Schiffmann JB Kopp HA Austin S Sabnis DF Moore T Weibel JE Balow RO Brady, JAMA 2001 285 2743 2749 10.1001/jama.285.21.2743 11386930
9. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. DP Germain S Waldek M Banikazemi DA Bushinsky J Charrow RJ Desnick P Lee T Loew AC Vedder R Abichandani WR Wilcox N Guffon, J Am Soc Nephrol 2007 18 1547 1557 10.1681/ASN.2006080816 17409312
10. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. T Takenaka G Qin RO Brady JA Medin, Hum Gene Ther 1999 10 1931 1939 10.1089/10430349950017293 10466627
11. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. RJ Ziegler NS Yew C Li M Cherry P Berthelette H Romanczuk YA Ioannou KM Zeidner RJ Desnick SH Cheng, Hum Gene Ther 1999 10 1667 1682 10.1089/10430349950017671 10428212
12. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. SC Jung IP Han A Limaye R Xu MP Gelderman P Zerfas K Tirumalai GJ Murray MJ During RO Brady P Qasba, Proc Natl Acad Sci USA 2001 98 2676 2681 10.1073/pnas.051634498 11226298
13. Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. RJ Ziegler M Cherry CM Barbon C Li SD Bercury D Armentano RJ Desnick SH Cheng, Mol Ther 2007 15 492 500 10.1038/sj.mt.6300066 17191071
14. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. G Gao Y Lu R Calcedo RL Grant P Bell L Wang J Figueredo M Lock JM Wilson, Mol Ther 2006 13 77 87 10.1016/j.ymthe.2005.08.017 16219492
15. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. MH Branton R Schiffmann SG Sabnis GJ Murray JM Quirk G Altarescu L Goldfarb RO Brady JE Balow HA Austin Iii JB Kopp, Medicine 2002 81 122 138 10.1097/00005792-200203000-00003 11889412
16. -Galactosidase A deficient mice: A model of Fabry disease. T Ohshima GJ Murray WD Swaim G Longenecker JM Quirk CO Cardarelli Y Sugimoto I Pastan MM Gottesman RO Brady AB Kulkarni, Proc Natl Acad Sci USA 1997 94 2540 2544 10.1073/pnas.94.6.2540 9122231
17. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. YA Ioannou KM Zeidner RE Gordon RJ Desnick, Am J Hum Genet 2001 68 14 25 10.1086/316953 11115376
18. Purification and properties of the two major isozymes of -galactosidase from human placenta. JW Kusiak JM Quirk RO Brady, J Biol Chem 1978 253 184 190 201618
19. Improved procedure for the extraction of lipids from human erythrocytes. HG Rose M Oklander, J Lipid Res 1965 6 428 431 14336214
20. Free/total prostate specific antigen ratio: a new hope. SK Shahi S Ranga SK Khurana VH Talib, Indian J Pathol Microbiol 1999 42 1 2 10420677
21. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. H Nakai S Fuess TA Storm S Muramatsu Y Nara MA Kay, J Virol 2005 79 214 224 10.1128/JVI.79.1.214-224.2005 15596817
22. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. A Pisani L Spinelli M Sabbatini MV Andreucci D Procaccini C Abbaterusso S Pasquali S Savoldi C Comotti B Cianciaruso, Am J Kidney Dis 2005 46 120 127 10.1053/j.ajkd.2005.03.016 15983965
23. Renal pathology in Fabry disease. J Alroy S Sabnis JB Kopp, J Am Soc Nephrol 2002 Suppl 2 134 138 12068025
24. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. H Nakai TA Storm MA Kay, J Virol 2000 74 9451 9463 10.1128/JVI.74.20.9451-9463.2000 11000214
25. Gene therapy using adeno-associated virus vectors. S Daya KI Berns, Clin Microbiol Rev 2008 21 583 593 10.1128/CMR.00008-08 18854481
26. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. RJ Ziegler SM Lonning D Armentano C Li DW Souza M Cherry C Ford CM Barbon RJ Desnick G Gao JM Wilson R Peluso S Godwin BJ Carter RJ Gregory SC Wadsworth SH Cheng, Mol Ther 2004 9 231 240 10.1016/j.ymthe.2003. 11.015 14759807
27. Generation and characterization of transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution causing a variant form of Fabry disease. M Shimmoto R Kase K Itoh K Utsumi S Ishii C Taya H Yonekawa H Sakuraba, Vision Res 1997 48 353 359
28. Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase. R Kase M Shimmoto K Itoh K Utsumi M Kotani C Taya H Yonekawa H Sakuraba, Biochim Biophys Acta 1998 1406 260 266 9630664
29. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. EI Christensen Q Zhou SS Sørensen AK Rasmussen C Jacobsen U Feldt-Rasmussen R Nielsen, J Am Soc Nephrol 2007 18 698 706 10.1681/ASN. 2006080822 17287429
30. Lysosomal storage diseases. EF Neufeld, Annu Rev Biochem 1991 60 257 280 10.1146/annurev.bi.60.070191.001353 1883197
31. Natural history and treatment of renal involvement in Fabry disease. M Branton R Schiffmann JB Kopp, J Am Soc Nephrol 2002 13 139 143 12068026
32. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. A Ortiz JP Oliveira C Wanner, Nat Clin Pract Nephrol 2008 4 327 336 10.1038/ncpneph0806 18431378
33. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. FC Fervenza R Torra DG Warnock, Biologics 2008 2 823 843 19707461
34. Subclinical Fabry's disease occurring in the context of IgA nephropathy. O Kawamura H Sakuraba K Itoh Y Suzuki M Doi H Kuwabara S Oshima S Abe H Warabi N Yoshizawa, Clin Nephrol 1997 47 71 75 9049452
35. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. H Tahir LL Jackson DG Warnock, J Am Soc Nephrol 2007 18 2609 2617 10.1681/ASN.2006121400 17656478
36. Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. N Clément DR Knop BJ Byrne, Hum Gene Ther 2009 20 796 806 10.1089/hum.2009.094 19569968